Correction to: Outcome for sinonasal malignancies: a population-based survey

Hafström, Anna; Sjövall, Johanna; Persson, Simon S.; Nilsson, Jens; Svensson, C.; Brun, Eva; Greiff, Lennart

doi:10.1007/s00405-022-07329-3

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with our patient, in whom occupational exposure was not evident. The adenocarcinoma variant has been shown to have a better survival than other rarer histological subtypes 16 17. Along with recurrent and metastatic disease, larger tumour size and nodal positivity are associated with poorer outcomes 14 16 18.…”

Section: Discussionmentioning

confidence: 99%

“…The adenocarcinoma variant has been shown to have a better survival than other rarer histological subtypes 16 17. Along with recurrent and metastatic disease, larger tumour size and nodal positivity are associated with poorer outcomes 14 16 18. Surgery and radiation are the mainstay of treatment for local disease, yet the addition of platinum-based chemotherapy has been shown to remarkably improve survival rates.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Low-dose nivolumab and cabozantinib in recurrent intestinal-type papillary adenocarcinoma of the sinonasal region

Thomas,

Jambunathan,

Jibi

et al. 2023

BMJ Case Rep

View full text Add to dashboard Cite

Intestinal-type sinonasal adenocarcinoma is a rare epithelial malignancy primarily treated with surgery and chemoradiation. The combination of low-dose immunotherapy and a tyrosine kinase inhibitor in recurrent disease has not been previously studied.A man in his 20s with papillary adenocarcinoma of the sinonasal region, following surgical resection, was treated with six cycles of concurrent chemoradiotherapy, followed by four cycles of docetaxel, cisplatin and capecitabine. While on treatment, he was found to have extensive residual disease and he was started on low-dose nivolumab and cabozantinib. Repeat imaging after ten months of treatment revealed a significant reduction in lesions.Non-squamous head and neck cancers are often excluded from major trials, and the effect of immunotherapy in these histologies is poorly understood. The response seen with low-dose immunotherapy underscores the need for further research in this setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%